首页 > 最新文献

Frontiers in nuclear medicine (Lausanne, Switzerland)最新文献

英文 中文
Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study. 铜-61 是体生长抑素受体表达肿瘤 PET 成像中镓-68 的优势替代品:一项头对头临床前比较研究。
Pub Date : 2024-10-11 eCollection Date: 2024-01-01 DOI: 10.3389/fnume.2024.1481343
Tais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, Raghuvir Haridas Gaonkar, Lisa McDougall, Anass Johayem, Milen Blagoev, Francesco De Rose, Leila Jaafar-Thiel, Melpomeni Fani
<p><strong>Background: </strong>Gallium-68 positron emission tomography (<sup>68</sup>Ga-PET) with the two registered somatostatin analogs, [<sup>68</sup>Ga]Ga-DOTA-Tyr<sup>3</sup>-octreotide ([<sup>68</sup>Ga]Ga-DOTA-TOC) and [<sup>68</sup>Ga]Ga-DOTA-Tyr<sup>3</sup>-octreotate ([<sup>68</sup>Ga]Ga-DOTA-TATE), where DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, is routinely used for imaging of somatostatin receptor (SST)-expressing tumors. We investigated copper-61 (<sup>61</sup>Cu) as an alternative radiometal for PET imaging of SST-expressing tumors. Compared to gallium-68, copper-61 (t<sub>1/2</sub> = 3.33 h, E <i><sub>β</sub></i> <sup>+</sup> <sub>max</sub> = 1.22 MeV) can be produced on a large scale, enables late time point imaging, and has the therapeutic twin copper-67. Herein, DOTA-TOC and 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA)-TOC were labeled with copper-61 and compared with the clinically used [<sup>68</sup>Ga]Ga-DOTA-TOC.</p><p><strong>Methods: </strong>[<sup>61</sup>Cu]CuCl<sub>2</sub> was produced from an irradiated natural nickel target. DOTA-TOC and NODAGA-TOC were labeled with [<sup>61</sup>Cu]CuCl<sub>2</sub> in ammonium acetate buffer so to achieve a reaction pH of 5-6 and a temperature of 95°C for DOTA-TOC or room temperature for NODAGA-TOC. The radioligands were evaluated head-to-head <i>in vitro</i> using human embryonic kidney (HEK)-SST<sub>2</sub> cells (affinity, binding sites, cellular uptake, and efflux) and <i>in vivo</i> using HEK-SST<sub>2</sub> xenografts [PET/computed tomography (CT) imaging, biodistribution, and pharmacokinetics] and compared with [<sup>68</sup>Ga]Ga-DOTA-TOC, which was prepared using a standard procedure. Dosimetry estimates were made for [<sup>61</sup>Cu]Cu-NODAGA-TOC.</p><p><strong>Results: </strong>[<sup>61</sup>Cu]Cu-DOTA-TOC and [<sup>61</sup>Cu]Cu-NODAGA-TOC were prepared at an apparent molar activity of 25 MBq/nmol with radiochemical purities of ≥96% and ≥98%, respectively. <i>In vitro</i>, both presented a sub-nanomolar affinity for SST<sub>2</sub> (IC<sub>50</sub> = 0.23 and 0.34 nM, respectively). They were almost entirely internalized upon binding to SST<sub>2</sub>-expressing cells and had similar efflux rates at 37°C. <i>In vivo</i>, [<sup>61</sup>Cu]Cu-DOTA-TOC and [<sup>61</sup>Cu]Cu-NODAGA-TOC showed the same accumulation in SST<sub>2</sub>-expressing tumors. However, PET/CT images and biodistribution analyses clearly showed an unfavorable biodistribution for [<sup>61</sup>Cu]Cu-DOTA-TOC, characterized by accumulation in the liver and the abdomen. [<sup>61</sup>Cu]Cu-NODAGA-TOC displayed favorable biodistribution, comparable with [<sup>68</sup>Ga]Ga-DOTA-TOC at 1 h post-injection (p.i.). Notwithstanding, [<sup>61</sup>Cu]Cu-NODAGA-TOC showed advantages at 4 h p.i., due to the tumor retention and improved tumor-to-non-tumor ratios. The effective dose (2.41 × 10<sup>-3</sup> mSv/MBq) of [<sup>61</sup>Cu]Cu-NODAGA-TOC, but also the dose t
背景:镓-68正电子发射断层扫描(68Ga-PET)使用两种注册的体生长激素类似物,即[68Ga]Ga-DOTA-Tyr3-octreotide([68Ga]Ga-DOTA-TOC)和[68Ga]Ga-DOTA-Tyr3-octreotate([68Ga]Ga-DOTA-TATE)、其中 DOTA = 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸,被常规用于表达体生长抑素受体(SST)的肿瘤成像。我们研究了铜-61(61Cu),将其作为表达 SST 的肿瘤 PET 成像的替代放射性金属。与镓-68相比,铜-61(t1/2 = 3.33 h,E β + max = 1.22 MeV)可以大规模生产,可以进行晚期时间点成像,并且具有治疗孪生铜-67的特性。在此,我们用铜-61标记了DOTA-TOC和1,4,7-三氮杂环壬烷,1-戊二酸-4,7-乙酸(NODAGA)-TOC,并与临床使用的[68Ga]Ga-DOTA-TOC进行了比较。在醋酸铵缓冲液中用[61Cu]CuCl2标记DOTA-TOC和NODAGA-TOC,使反应pH值达到5-6,DOTA-TOC的反应温度为95°C,NODAGA-TOC的反应温度为室温。利用人体胚胎肾(HEK)-SST2 细胞(亲和力、结合位点、细胞摄取和外流)和 HEK-SST2 异种移植物(体内)[PET/计算机断层扫描(CT)成像、生物分布和药代动力学]对这些放射性配体进行了正面评估,并与采用标准程序制备的[68Ga]Ga-DOTA-TOC 进行了比较。对[61Cu]Cu-NODAGA-TOC进行了剂量估算:结果:[61Cu]Cu-DOTA-TOC 和 [61Cu]Cu-NODAGA-TOC 的表观摩尔活度为 25 MBq/nmol,放射化学纯度分别为≥96%和≥98%。在体外,这两种药物对 SST2 的亲和力都在纳摩尔以下(IC50 = 0.23 和 0.34 nM)。它们与表达 SST2 的细胞结合后几乎完全内化,在 37°C 时的外流率相似。在体内,[61Cu]Cu-DOTA-TOC 和[61Cu]Cu-NODAGA-TOC 在表达 SST2 的肿瘤中显示出相同的蓄积。然而,PET/CT 图像和生物分布分析清楚地表明,[61Cu]Cu-DOTA-TOC 的生物分布不利,其特点是在肝脏和腹部聚集。[61Cu]Cu-NODAGA-TOC显示出良好的生物分布,在注射后1小时与[68Ga]Ga-DOTA-TOC相当。尽管如此,[61Cu]Cu-NODAGA-TOC在注射后4小时仍显示出优势,这是因为肿瘤保留率和肿瘤与非肿瘤的比率得到了改善。61Cu]Cu-NODAGA-TOC的有效剂量(2.41×10-3 mSv/MBq)以及其他器官和肾脏的剂量(9.65×10-2 mGy/MBq)都表明其安全性良好:结论:61Cu-PET 成像不仅能与 68Ga-PET 在 1 小时内的成像效果相媲美,而且在 4 小时内的晚期成像中也具有优势,因为它能提高肿瘤与非肿瘤的比例。在体内,[61Cu]Cu-NODAGA-TOC优于[61Cu]Cu-DOTA-TOC。使用螯合剂 NODAGA 可以在室温下对铜-61 进行定量标记,并能直接使用试剂盒配方,方便医疗中心的生产。
{"title":"Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.","authors":"Tais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, Raghuvir Haridas Gaonkar, Lisa McDougall, Anass Johayem, Milen Blagoev, Francesco De Rose, Leila Jaafar-Thiel, Melpomeni Fani","doi":"10.3389/fnume.2024.1481343","DOIUrl":"10.3389/fnume.2024.1481343","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Gallium-68 positron emission tomography (&lt;sup&gt;68&lt;/sup&gt;Ga-PET) with the two registered somatostatin analogs, [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-Tyr&lt;sup&gt;3&lt;/sup&gt;-octreotide ([&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TOC) and [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-Tyr&lt;sup&gt;3&lt;/sup&gt;-octreotate ([&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TATE), where DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, is routinely used for imaging of somatostatin receptor (SST)-expressing tumors. We investigated copper-61 (&lt;sup&gt;61&lt;/sup&gt;Cu) as an alternative radiometal for PET imaging of SST-expressing tumors. Compared to gallium-68, copper-61 (t&lt;sub&gt;1/2&lt;/sub&gt; = 3.33 h, E &lt;i&gt;&lt;sub&gt;β&lt;/sub&gt;&lt;/i&gt; &lt;sup&gt;+&lt;/sup&gt; &lt;sub&gt;max&lt;/sub&gt; = 1.22 MeV) can be produced on a large scale, enables late time point imaging, and has the therapeutic twin copper-67. Herein, DOTA-TOC and 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA)-TOC were labeled with copper-61 and compared with the clinically used [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TOC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;[&lt;sup&gt;61&lt;/sup&gt;Cu]CuCl&lt;sub&gt;2&lt;/sub&gt; was produced from an irradiated natural nickel target. DOTA-TOC and NODAGA-TOC were labeled with [&lt;sup&gt;61&lt;/sup&gt;Cu]CuCl&lt;sub&gt;2&lt;/sub&gt; in ammonium acetate buffer so to achieve a reaction pH of 5-6 and a temperature of 95°C for DOTA-TOC or room temperature for NODAGA-TOC. The radioligands were evaluated head-to-head &lt;i&gt;in vitro&lt;/i&gt; using human embryonic kidney (HEK)-SST&lt;sub&gt;2&lt;/sub&gt; cells (affinity, binding sites, cellular uptake, and efflux) and &lt;i&gt;in vivo&lt;/i&gt; using HEK-SST&lt;sub&gt;2&lt;/sub&gt; xenografts [PET/computed tomography (CT) imaging, biodistribution, and pharmacokinetics] and compared with [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TOC, which was prepared using a standard procedure. Dosimetry estimates were made for [&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-NODAGA-TOC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;[&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-DOTA-TOC and [&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-NODAGA-TOC were prepared at an apparent molar activity of 25 MBq/nmol with radiochemical purities of ≥96% and ≥98%, respectively. &lt;i&gt;In vitro&lt;/i&gt;, both presented a sub-nanomolar affinity for SST&lt;sub&gt;2&lt;/sub&gt; (IC&lt;sub&gt;50&lt;/sub&gt; = 0.23 and 0.34 nM, respectively). They were almost entirely internalized upon binding to SST&lt;sub&gt;2&lt;/sub&gt;-expressing cells and had similar efflux rates at 37°C. &lt;i&gt;In vivo&lt;/i&gt;, [&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-DOTA-TOC and [&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-NODAGA-TOC showed the same accumulation in SST&lt;sub&gt;2&lt;/sub&gt;-expressing tumors. However, PET/CT images and biodistribution analyses clearly showed an unfavorable biodistribution for [&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-DOTA-TOC, characterized by accumulation in the liver and the abdomen. [&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-NODAGA-TOC displayed favorable biodistribution, comparable with [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TOC at 1 h post-injection (p.i.). Notwithstanding, [&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-NODAGA-TOC showed advantages at 4 h p.i., due to the tumor retention and improved tumor-to-non-tumor ratios. The effective dose (2.41 × 10&lt;sup&gt;-3&lt;/sup&gt; mSv/MBq) of [&lt;sup&gt;61&lt;/sup&gt;Cu]Cu-NODAGA-TOC, but also the dose t","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"4 ","pages":"1481343"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142514127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mixture prior distributions and Bayesian models for robust radionuclide image processing. 用于稳健放射性核素图像处理的混合先验分布和贝叶斯模型。
Pub Date : 2024-09-05 eCollection Date: 2024-01-01 DOI: 10.3389/fnume.2024.1380518
Muyang Zhang, Robert G Aykroyd, Charalampos Tsoumpas

The diagnosis of medical conditions and subsequent treatment often involves radionuclide imaging techniques. To refine localisation accuracy and improve diagnostic confidence, compared with the use of a single scanning technique, a combination of two (or more) techniques can be used but with a higher risk of misalignment. For this to be reliable and accurate, recorded data undergo processing to suppress noise and enhance resolution. A step in image processing techniques for such inverse problems is the inclusion of smoothing. Standard approaches, however, are usually limited to applying identical models globally. In this study, we propose a novel Laplace and Gaussian mixture prior distribution that incorporates different smoothing strategies with the automatic model-based estimation of mixture component weightings creating a locally adaptive model. A fully Bayesian approach is presented using multi-level hierarchical modelling and Markov chain Monte Carlo (MCMC) estimation methods to sample from the posterior distribution and hence perform estimation. The proposed methods are assessed using simulated γ -eye TM camera images and demonstrate greater noise reduction than existing methods but without compromising resolution. As well as image estimates, the MCMC methods also provide posterior variance estimates and hence uncertainty quantification takes into consideration any potential sources of variability. The use of mixture prior models, part Laplace random field and part Gaussian random field, within a Bayesian modelling approach is not limited to medical imaging applications but provides a more general framework for analysing other spatial inverse problems. Locally adaptive prior distributions provide a more realistic model, which leads to robust results and hence more reliable decision-making, especially in nuclear medicine. They can become a standard part of the toolkit of everyone working in image processing applications.

医学病症的诊断和随后的治疗通常涉及放射性核素成像技术。为了提高定位的准确性和诊断的可信度,与使用单一的扫描技术相比,可以结合使用两种(或多种)技术,但错位的风险较高。为了保证可靠和准确,记录的数据需要经过处理,以抑制噪音和提高分辨率。针对此类逆问题的图像处理技术的一个步骤就是加入平滑处理。然而,标准方法通常仅限于在全局范围内应用相同的模型。在本研究中,我们提出了一种新颖的拉普拉斯和高斯混合先验分布,它将不同的平滑策略与基于模型的混合成分权重自动估算相结合,创建了一个局部自适应模型。我们提出了一种全贝叶斯方法,使用多级分层建模和马尔科夫链蒙特卡罗(MCMC)估计方法从后验分布中采样,从而进行估计。使用模拟的 γ -eye TM 相机图像对所提出的方法进行了评估,结果表明,与现有方法相比,该方法能在不影响分辨率的情况下更大程度地降低噪声。除了图像估计,MCMC 方法还提供了后验方差估计,因此不确定性量化考虑到了任何潜在的变异源。在贝叶斯建模方法中使用混合先验模型,即部分拉普拉斯随机场和部分高斯随机场,并不局限于医学成像应用,而是为分析其他空间逆问题提供了一个更通用的框架。局部自适应先验分布提供了一个更现实的模型,从而得出稳健的结果,并因此做出更可靠的决策,尤其是在核医学领域。它们可以成为从事图像处理应用的每个人的标准工具包。
{"title":"Mixture prior distributions and Bayesian models for robust radionuclide image processing.","authors":"Muyang Zhang, Robert G Aykroyd, Charalampos Tsoumpas","doi":"10.3389/fnume.2024.1380518","DOIUrl":"10.3389/fnume.2024.1380518","url":null,"abstract":"<p><p>The diagnosis of medical conditions and subsequent treatment often involves radionuclide imaging techniques. To refine localisation accuracy and improve diagnostic confidence, compared with the use of a single scanning technique, a combination of two (or more) techniques can be used but with a higher risk of misalignment. For this to be reliable and accurate, recorded data undergo processing to suppress noise and enhance resolution. A step in image processing techniques for such inverse problems is the inclusion of smoothing. Standard approaches, however, are usually limited to applying identical models globally. In this study, we propose a novel Laplace and Gaussian mixture prior distribution that incorporates different smoothing strategies with the automatic model-based estimation of mixture component weightings creating a locally adaptive model. A fully Bayesian approach is presented using multi-level hierarchical modelling and Markov chain Monte Carlo (MCMC) estimation methods to sample from the posterior distribution and hence perform estimation. The proposed methods are assessed using simulated <math><mi>γ</mi> <msup><mtext>-eye</mtext> <mrow><mtext>TM</mtext></mrow> </msup> </math> camera images and demonstrate greater noise reduction than existing methods but without compromising resolution. As well as image estimates, the MCMC methods also provide posterior variance estimates and hence uncertainty quantification takes into consideration any potential sources of variability. The use of mixture prior models, part Laplace random field and part Gaussian random field, within a Bayesian modelling approach is not limited to medical imaging applications but provides a more general framework for analysing other spatial inverse problems. Locally adaptive prior distributions provide a more realistic model, which leads to robust results and hence more reliable decision-making, especially in nuclear medicine. They can become a standard part of the toolkit of everyone working in image processing applications.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"4 ","pages":"1380518"},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Application of 18F-FDG PET/CT in identifying plasmacytoma in monoclonal gammopathy associated peripheral neuropathy. 病例报告:应用 18F-FDG PET/CT 鉴别单克隆丙种球蛋白病相关周围神经病变中的浆细胞瘤。
Pub Date : 2024-08-14 eCollection Date: 2024-01-01 DOI: 10.3389/fnume.2024.1446780
Jiequn Weng, Jie Lin, Chong Sun

Peripheral neuropathy is a prevalent complication in plasma cell disorders, posing significant diagnostic and therapeutic challenges. This study presents three cases initially diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite initial symptom regression post-immunomodulatory treatment, the patients exhibited progressive neurological deficits. Advanced laboratory evaluation confirmed monoclonal protein presence, yet traditional diagnostic methods, including bone marrow biopsy and flow cytometry, yielded normal results. Utilizing 18F-FDG PET/CT, we identified multiple hypermetabolic vertebral lesions, which upon biopsy, confirmed the diagnosis of plasmacytoma. Our findings underscore the utility of PET/CT as a reliable diagnostic tool for monoclonal gammopathy associated neuropathy, advocating for its consideration in cases with equivocal diagnosis. When the diagnosis is in doubt, biopsy of a lesion may facilitate early and accurate diagnosis, potentially influencing treatment strategies and patient outcomes.

周围神经病变是浆细胞疾病的一种常见并发症,给诊断和治疗带来了巨大挑战。本研究介绍了三例最初被诊断为慢性炎症性脱髓鞘性多发性神经病(CIDP)的病例。尽管经过免疫调节治疗后,患者最初的症状有所缓解,但仍表现出进行性神经功能缺损。先进的实验室评估证实了单克隆蛋白的存在,但包括骨髓活检和流式细胞术在内的传统诊断方法结果正常。利用18F-FDG PET/CT,我们发现了多个高代谢椎体病变,活检后确诊为浆细胞瘤。我们的研究结果强调了 PET/CT 作为单克隆丙种球蛋白病相关神经病的可靠诊断工具的实用性,主张在诊断不明确的病例中考虑使用 PET/CT。当诊断存在疑问时,对病灶进行活检可有助于早期准确诊断,从而对治疗策略和患者预后产生潜在影响。
{"title":"Case Report: Application of <sup>18</sup>F-FDG PET/CT in identifying plasmacytoma in monoclonal gammopathy associated peripheral neuropathy.","authors":"Jiequn Weng, Jie Lin, Chong Sun","doi":"10.3389/fnume.2024.1446780","DOIUrl":"10.3389/fnume.2024.1446780","url":null,"abstract":"<p><p>Peripheral neuropathy is a prevalent complication in plasma cell disorders, posing significant diagnostic and therapeutic challenges. This study presents three cases initially diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite initial symptom regression post-immunomodulatory treatment, the patients exhibited progressive neurological deficits. Advanced laboratory evaluation confirmed monoclonal protein presence, yet traditional diagnostic methods, including bone marrow biopsy and flow cytometry, yielded normal results. Utilizing <sup>18</sup>F-FDG PET/CT, we identified multiple hypermetabolic vertebral lesions, which upon biopsy, confirmed the diagnosis of plasmacytoma. Our findings underscore the utility of PET/CT as a reliable diagnostic tool for monoclonal gammopathy associated neuropathy, advocating for its consideration in cases with equivocal diagnosis. When the diagnosis is in doubt, biopsy of a lesion may facilitate early and accurate diagnosis, potentially influencing treatment strategies and patient outcomes.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"4 ","pages":"1446780"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report: positive pitfalls of PSMA PET/CT: diagnostic challenges in degenerative bone lesions including MODIC type 1. 病例报告:PSMA PET/CT 的阳性陷阱:包括 MODIC 1 型在内的骨退行性病变的诊断难题。
Pub Date : 2024-08-02 eCollection Date: 2024-01-01 DOI: 10.3389/fnume.2024.1451848
Hicham Moukaddam, Ghida El Saheb, Nadine Omran, Nour El Ghawi, Alain Abi Ghanem, Mohamad Haidar

Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an imaging technique that has demonstrated high sensitivity and specificity in detecting prostate cancer and its metastasis, especially in the bones. This case describes a 60-year-old man who presented for increased prostate-specific antigen (PSA) level and underwent [68Ga]gallium-PSMA-11 PET/CT imaging for better disease assessment. 68Ga-PSMA-11 PET/CT revealed numerous radiotracer-positive lesions in both prostate lobes with associated sclerotic lesions on L4 and L5, but only L5 showed increased radiotracer avidity raising the possibility of metastasis. Magnetic Resonance Imaging (MRI) raises the possibility of aggressive MODIC type 1 lesion vs. infectious/inflammatory process. A biopsy of the radiotracer avid area was performed and showed no evidence of metastasis. The final diagnosis was aggressive MODIC type 1, in keeping with the false positive result of 68Ga-PSMA-11 PET/CT. This example demonstrates the possible limitations of 68Ga-PSMA-11 PET/CT, particularly in detecting bone metastases, and emphasizes the need for cautious interpretation and additional study to improve its diagnostic accuracy. Understanding and resolving these limitations is critical for increasing the accuracy of PSMA PET/CT in prostate cancer management.

前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)是一种成像技术,在检测前列腺癌及其转移(尤其是骨转移)方面具有很高的灵敏度和特异性。本病例描述了一名 60 岁男性因前列腺特异性抗原(PSA)水平升高而接受[68Ga]镓-PSMA-11 PET/CT 成像检查,以更好地评估疾病。68Ga-PSMA-11 PET/CT 显示,两个前列腺叶均有大量放射性示踪剂阳性病变,L4 和 L5 有相关硬化病变,但只有 L5 显示放射性示踪剂嗜性增加,这提高了转移的可能性。磁共振成像(MRI)显示可能是侵袭性 MODIC 1 型病变或感染/炎症过程。对放射性示踪剂阳性区域进行了活检,结果显示没有转移迹象。最终诊断为侵袭性 MODIC 1 型,与 68Ga-PSMA-11 PET/CT 的假阳性结果一致。这个例子说明了68Ga-PSMA-11 PET/CT可能存在的局限性,尤其是在检测骨转移方面,并强调了谨慎解释和进行更多研究以提高诊断准确性的必要性。了解并解决这些局限性对于提高 PSMA PET/CT 在前列腺癌治疗中的准确性至关重要。
{"title":"Case report: positive pitfalls of PSMA PET/CT: diagnostic challenges in degenerative bone lesions including MODIC type 1.","authors":"Hicham Moukaddam, Ghida El Saheb, Nadine Omran, Nour El Ghawi, Alain Abi Ghanem, Mohamad Haidar","doi":"10.3389/fnume.2024.1451848","DOIUrl":"10.3389/fnume.2024.1451848","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an imaging technique that has demonstrated high sensitivity and specificity in detecting prostate cancer and its metastasis, especially in the bones. This case describes a 60-year-old man who presented for increased prostate-specific antigen (PSA) level and underwent [<sup>68</sup>Ga]gallium-PSMA-11 PET/CT imaging for better disease assessment. <sup>68</sup>Ga-PSMA-11 PET/CT revealed numerous radiotracer-positive lesions in both prostate lobes with associated sclerotic lesions on L4 and L5, but only L5 showed increased radiotracer avidity raising the possibility of metastasis. Magnetic Resonance Imaging (MRI) raises the possibility of aggressive MODIC type 1 lesion vs. infectious/inflammatory process. A biopsy of the radiotracer avid area was performed and showed no evidence of metastasis. The final diagnosis was aggressive MODIC type 1, in keeping with the false positive result of <sup>68</sup>Ga-PSMA-11 PET/CT. This example demonstrates the possible limitations of <sup>68</sup>Ga-PSMA-11 PET/CT, particularly in detecting bone metastases, and emphasizes the need for cautious interpretation and additional study to improve its diagnostic accuracy. Understanding and resolving these limitations is critical for increasing the accuracy of PSMA PET/CT in prostate cancer management.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"4 ","pages":"1451848"},"PeriodicalIF":0.0,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PARALLELPROJ-an open-source framework for fast calculation of projections in tomography. PARALLELPROJ - 用于快速计算断层扫描投影的开源框架。
Pub Date : 2024-01-08 eCollection Date: 2023-01-01 DOI: 10.3389/fnume.2023.1324562
Georg Schramm, Kris Thielemans

In this article, we introduce parallelproj, a novel open-source framework designed for efficient parallel computation of projections in tomography leveraging either multiple CPU cores or GPUs. This framework efficiently implements forward and back projection functions for both sinogram and listmode data, utilizing Joseph's method, which is further extended to encompass time-of-flight (TOF) PET projections. Our evaluation involves a series of tests focusing on PET image reconstruction using data sourced from a state-of-the-art clinical PET/CT system. We thoroughly benchmark the performance of the projectors in non-TOF and TOF, sinogram, and listmode employing multi CPU-cores, hybrid CPU/GPU, and exclusive GPU mode. Moreover, we also investigate the timing of non-TOF sinogram projections calculated in STIR (Software for Tomographic Image Reconstruction) which recently integrated parallelproj as one of its projection backends. Our results indicate that the exclusive GPU mode provides acceleration factors between 25 and 68 relative to the multi-CPU-core mode. Furthermore, we demonstrate that OSEM listmode reconstruction of state-of-the-art real-world PET data sets is achievable within a few seconds using a single consumer GPU.

在本文中,我们将介绍一个新颖的开源框架--parallelproj,该框架旨在利用多个 CPU 内核或 GPU 高效并行计算断层摄影中的投影。该框架利用约瑟夫方法有效地实现了正弦图和列表模式数据的正向和反向投影功能,并进一步扩展到飞行时间(TOF)PET 投影。我们的评估包括一系列测试,重点是使用来自最先进的临床 PET/CT 系统的数据重建 PET 图像。我们采用多 CPU 核、CPU/GPU 混合模式和独占 GPU 模式,对投影仪在非 TOF 和 TOF、正弦图和列表模式下的性能进行了全面的基准测试。此外,我们还研究了在 STIR(断层图像重建软件)中计算的非 TOF 正弦曲线投影的时序,该软件最近集成了 parallelproj 作为其投影后端之一。我们的研究结果表明,相对于多 CPU 内核模式,独占 GPU 模式可提供 25 到 68 倍的加速度。此外,我们还证明了使用单个消费级 GPU 在几秒钟内就能完成最先进的真实 PET 数据集的 OSEM 列表模式重建。
{"title":"PARALLELPROJ-an open-source framework for fast calculation of projections in tomography.","authors":"Georg Schramm, Kris Thielemans","doi":"10.3389/fnume.2023.1324562","DOIUrl":"10.3389/fnume.2023.1324562","url":null,"abstract":"<p><p>In this article, we introduce parallelproj, a novel open-source framework designed for efficient parallel computation of projections in tomography leveraging either multiple CPU cores or GPUs. This framework efficiently implements forward and back projection functions for both sinogram and listmode data, utilizing Joseph's method, which is further extended to encompass time-of-flight (TOF) PET projections. Our evaluation involves a series of tests focusing on PET image reconstruction using data sourced from a state-of-the-art clinical PET/CT system. We thoroughly benchmark the performance of the projectors in non-TOF and TOF, sinogram, and listmode employing multi CPU-cores, hybrid CPU/GPU, and exclusive GPU mode. Moreover, we also investigate the timing of non-TOF sinogram projections calculated in STIR (Software for Tomographic Image Reconstruction) which recently integrated parallelproj as one of its projection backends. Our results indicate that the exclusive GPU mode provides acceleration factors between 25 and 68 relative to the multi-CPU-core mode. Furthermore, we demonstrate that OSEM listmode reconstruction of state-of-the-art real-world PET data sets is achievable within a few seconds using a single consumer GPU.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"3 ","pages":"1324562"},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data. 利用预先计算的单粒子轨迹标准 DNA 损伤数据,对放射性核素靶向治疗中的放射生物学效应进行逐个细胞的快速蒙特卡洛模拟。
Pub Date : 2023-12-06 eCollection Date: 2023-01-01 DOI: 10.3389/fnume.2023.1284558
A Lim, M Andriotty, T Yusufaly, G Agasthya, B Lee, C Wang

Introduction: We developed a new method that drastically speeds up radiobiological Monte Carlo radiation-track-structure (MC-RTS) calculations on a cell-by-cell basis.

Methods: The technique is based on random sampling and superposition of single-particle track (SPT) standard DNA damage (SDD) files from a "pre-calculated" data library, constructed using the RTS code TOPAS-nBio, with "time stamps" manually added to incorporate dose-rate effects. This time-stamped SDD file can then be input into MEDRAS, a mechanistic kinetic model that calculates various radiation-induced biological endpoints, such as DNA double-strand breaks (DSBs), misrepairs and chromosomal aberrations, and cell death. As a benchmark validation of the approach, we calculated the predicted energy-dependent DSB yield and the ratio of direct-to-total DNA damage, both of which agreed with published in vitro experimental data. We subsequently applied the method to perform a superfast cell-by-cell simulation of an experimental in vitro system consisting of neuroendocrine tumor cells uniformly incubated with 177Lu.

Results and discussion: The results for residual DSBs, both at 24 and 48 h post-irradiation, are in line with the published literature values. Our work serves as a proof-of-concept demonstration of the feasibility of a cost-effective "in silico clonogenic cell survival assay" for the computational design and development of radiopharmaceuticals and novel radiotherapy treatments more generally.

简介:我们开发了一种新方法,可大幅加快放射生物学蒙特卡洛辐射轨迹结构(MC-RTS)计算的速度:我们开发了一种新方法,可大大加快逐个细胞的放射生物学蒙特卡洛辐射轨迹结构(MC-RTS)计算速度:该技术基于随机抽样和单粒子轨道(SPT)标准 DNA 损伤(SDD)文件的叠加,这些文件来自使用 RTS 代码 TOPAS-nBio 构建的 "预计算 "数据文件库,并人工添加了 "时间戳 "以纳入剂量率效应。这种带有时间戳的 SDD 文件随后可输入 MEDRAS,这是一种机理动力学模型,可计算各种辐射诱导的生物终点,如 DNA 双链断裂(DSB)、错误修复和染色体畸变以及细胞死亡。作为该方法的基准验证,我们计算了预测的随能量变化的DSB产量和DNA直接损伤与总损伤之比,两者均与已发表的体外实验数据一致。随后,我们应用该方法对神经内分泌肿瘤细胞均匀培养 177Lu 的体外实验系统进行了逐个细胞的超快速模拟:辐照后24小时和48小时的残余DSB结果与已发表的文献值一致。我们的工作证明了经济有效的 "硅学克隆细胞存活测定 "的可行性,可用于放射性药物和新型放射治疗方法的计算设计和开发。
{"title":"A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data.","authors":"A Lim, M Andriotty, T Yusufaly, G Agasthya, B Lee, C Wang","doi":"10.3389/fnume.2023.1284558","DOIUrl":"10.3389/fnume.2023.1284558","url":null,"abstract":"<p><strong>Introduction: </strong>We developed a new method that drastically speeds up radiobiological Monte Carlo radiation-track-structure (MC-RTS) calculations on a cell-by-cell basis.</p><p><strong>Methods: </strong>The technique is based on random sampling and superposition of single-particle track (SPT) standard DNA damage (SDD) files from a \"pre-calculated\" data library, constructed using the RTS code TOPAS-nBio, with \"time stamps\" manually added to incorporate dose-rate effects. This time-stamped SDD file can then be input into MEDRAS, a mechanistic kinetic model that calculates various radiation-induced biological endpoints, such as DNA double-strand breaks (DSBs), misrepairs and chromosomal aberrations, and cell death. As a benchmark validation of the approach, we calculated the predicted energy-dependent DSB yield and the ratio of direct-to-total DNA damage, both of which agreed with published <i>in vitro</i> experimental data. We subsequently applied the method to perform a superfast cell-by-cell simulation of an experimental <i>in vitro</i> system consisting of neuroendocrine tumor cells uniformly incubated with <sup>177</sup>Lu.</p><p><strong>Results and discussion: </strong>The results for residual DSBs, both at 24 and 48 h post-irradiation, are in line with the published literature values. Our work serves as a proof-of-concept demonstration of the feasibility of a cost-effective \"<i>in silico</i> clonogenic cell survival assay\" for the computational design and development of radiopharmaceuticals and novel radiotherapy treatments more generally.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"3 ","pages":"1284558"},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Post-traumatic splenosis and potential pitfall for PSMA-PET. 病例报告:创伤后脾肿大和 PSMA-PET 的潜在隐患。
Pub Date : 2023-11-27 eCollection Date: 2023-01-01 DOI: 10.3389/fnume.2023.1319952
Marina Nearchou, Elizabeth Georgiou, Alexis Vrachimis, Konstantinos Ferentinos, Iosif Strouthos

Background: 18F-prostate specific membrane antigen (PSMA) PET is fast becoming the gold-standard in prostate cancer, both in staging of intermediate-/high-risk patients and in re-staging patients with biochemical failure. Several pitfalls of 18F-PSMA PET have been reported, and we report, to our best of knowledge, for the first time, a case which could have been falsely diagnosed as peritoneal spread.

Case presentation: A 67-year-old patient with high-risk prostate cancer underwent staging with 18F-PSMA-1007 PET/CT (PSMA-PET/CT). PSMA-PET/CT revealed a histologically confirmed prostatic malignancy in the peripheral left zone. Unexpectedly, additional multiple highly PSMA-expressing intraabdominal formations were discovered. Based on apparent anatomic asplenia and a history of traumatic splenic rapture during childhood, a suspicion of post-traumatic splenosis was raised. For further non-invasive evaluation, a C-99 sulphur colloid scintigraphy with SPECT was conducted, confirming the presence of multiple functional ectopic splenic tissues. This is, to our best of knowledge, the first case utilising 18F-PSMA-1007-PET/CT and 99mTc-sulphur colloid SPECT to detect intraabdominal splenosis, highlighting the high potential of nuclear medicine in such trivial cases.

背景:18F-前列腺特异性膜抗原(PSMA)PET正迅速成为前列腺癌的金标准,既可用于中/高危患者的分期,也可用于生化检查失败患者的再分期。据我们所知,我们首次报告了一例可能被误诊为腹膜扩散的病例:一名 67 岁的高危前列腺癌患者接受了 18F-PSMA-1007 PET/CT (PSMA-PET/CT)分期检查。PSMA-PET/CT显示,经组织学证实的前列腺恶性肿瘤位于左侧外周区。意想不到的是,患者腹腔内还发现了多个高 PSMA 表达的肿瘤。基于明显的解剖学脾肿大和儿童时期的外伤性脾脏破裂病史,该患者被怀疑患有外伤后脾肿大。为了进行进一步的非侵入性评估,患者接受了 C-99 硫胶体闪烁扫描和 SPECT 检查,结果证实存在多个功能性异位脾组织。据我们所知,这是首例利用 18F-PSMA-1007-PET/CT 和 99mTc 硫胶体 SPECT 检测腹腔内脾脏病变的病例,凸显了核医学在此类琐碎病例中的巨大潜力。
{"title":"Case Report: Post-traumatic splenosis and potential pitfall for PSMA-PET.","authors":"Marina Nearchou, Elizabeth Georgiou, Alexis Vrachimis, Konstantinos Ferentinos, Iosif Strouthos","doi":"10.3389/fnume.2023.1319952","DOIUrl":"10.3389/fnume.2023.1319952","url":null,"abstract":"<p><strong>Background: </strong>18F-prostate specific membrane antigen (PSMA) PET is fast becoming the gold-standard in prostate cancer, both in staging of intermediate-/high-risk patients and in re-staging patients with biochemical failure. Several pitfalls of 18F-PSMA PET have been reported, and we report, to our best of knowledge, for the first time, a case which could have been falsely diagnosed as peritoneal spread.</p><p><strong>Case presentation: </strong>A 67-year-old patient with high-risk prostate cancer underwent staging with 18F-PSMA-1007 PET/CT (PSMA-PET/CT). PSMA-PET/CT revealed a histologically confirmed prostatic malignancy in the peripheral left zone. Unexpectedly, additional multiple highly PSMA-expressing intraabdominal formations were discovered. Based on apparent anatomic asplenia and a history of traumatic splenic rapture during childhood, a suspicion of post-traumatic splenosis was raised. For further non-invasive evaluation, a C-99 sulphur colloid scintigraphy with SPECT was conducted, confirming the presence of multiple functional ectopic splenic tissues. This is, to our best of knowledge, the first case utilising 18F-PSMA-1007-PET/CT and 99mTc-sulphur colloid SPECT to detect intraabdominal splenosis, highlighting the high potential of nuclear medicine in such trivial cases.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"3 ","pages":"1319952"},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First use of 18F-FDG PET in TEMPI syndrome: can it be used for treatment assessment? A case report 18F-FDG PET在TEMPI综合征中的首次应用:能否用于治疗评估?病例报告
Pub Date : 2023-10-26 DOI: 10.3389/fnume.2023.1273967
Henri Pasquesoone, Aurélien Callaud, Thibaut Carsuzaa, Thomas Chalopin, Maria-Joao Santiago-Ribeiro
TEMPI syndrome (TEMPI) compounds telangiectasias and polycythemia with elevated erythropoietin levels, monoclonal gammopathy, perirenal fluid collections, and intrapulmonary shunt. Although the pathophysiology of this syndrome remains unclarified, prior research has been established that it is a plasma cell neoplasm, often containing less than 10% bone marrow plasma cells. 18 F-FDG PET serves as a valuable instrument for initial staging and treatment monitoring in multiple myeloma management. Thus, 18 F-FDG PET can be legitimately applied for TEMPI assessment. Here, we present the first 18 F-FDG PET images for the initial evaluation and treatment monitoring of TEMPI in a 51-year-old woman, who exhibited polycythemia (EPO:5,448 mIU/ml) without JAK2 mutation, telangiectasias, monoclonal IgG lambda gammopathy (13.9) g/L and 7% dysmorphic plasma cells (CD38 + CD138+), occasionally clustered, in favor of tumoral plasmacytomas. The first PET scan exhibited hypermetabolic diffuse bone marrow, potentially related to polycythemia, accompanied by non-lytic bone hypermetabolic lesions in the femoral and humeral diaphysis, and ametabolic peri-renal fluid collections, brown fat, and pleural talcoma. Post-treatment 18 F-FDG PET (Daratumumab Bortezomib Thalidomide Dexamethasone) revealed a completely reduced signal of bone lesions, suggesting a complete response, which was substantiated both clinically and biologically, with the concurrent disappearance of telangiectasia and the monoclonal component, and the normalization of the EPO level. In future, additional data will be required to confirm the added value of 18 F-FDG PET with TEMPI. Nevertheless, 18 F-FDG PET can be a preferred tool for the extension workup and therapeutic evaluation of TEMPI syndrome.
TEMPI综合征(TEMPI)由毛细血管扩张和红细胞增多症合并促红细胞生成素水平升高、单克隆伽玛病、肾周积液和肺内分流引起。虽然该综合征的病理生理尚不清楚,但先前的研究已经确定它是一种浆细胞肿瘤,通常含有少于10%的骨髓浆细胞。18 F-FDG PET在多发性骨髓瘤的初始分期和治疗监测中具有重要作用。因此,18个F-FDG PET可以合法申请进行TEMPI评估。在这里,我们展示了一名51岁女性的第一次18张F-FDG PET图像,用于初步评估和治疗监测TEMPI,她表现为红细胞增多症(EPO:5,448 mIU/ml),无JAK2突变,毛细血管扩张,单克隆IgG λ γ病(13.9)g/L和7%畸形浆细胞(CD38 + CD138+),偶尔聚集,有利于肿瘤浆细胞瘤。第一次PET扫描显示高代谢性弥漫性骨髓,可能与红细胞增多症有关,伴股骨干和肱骨骨干非溶解性骨高代谢性病变,以及代谢性肾周积液、棕色脂肪和胸膜肉瘤。治疗后18 F-FDG PET (Daratumumab Bortezomib Thalidomide Dexamethasone)显示骨病变信号完全减少,表明完全缓解,这在临床和生物学上都得到证实,毛细血管扩张和单克隆成分同时消失,EPO水平正常化。未来,将需要额外的数据来确认18 F-FDG PET与TEMPI的附加值。尽管如此,18f - fdg PET可以作为temi综合征扩展检查和治疗评估的首选工具。
{"title":"First use of 18F-FDG PET in TEMPI syndrome: can it be used for treatment assessment? A case report","authors":"Henri Pasquesoone, Aurélien Callaud, Thibaut Carsuzaa, Thomas Chalopin, Maria-Joao Santiago-Ribeiro","doi":"10.3389/fnume.2023.1273967","DOIUrl":"https://doi.org/10.3389/fnume.2023.1273967","url":null,"abstract":"TEMPI syndrome (TEMPI) compounds telangiectasias and polycythemia with elevated erythropoietin levels, monoclonal gammopathy, perirenal fluid collections, and intrapulmonary shunt. Although the pathophysiology of this syndrome remains unclarified, prior research has been established that it is a plasma cell neoplasm, often containing less than 10% bone marrow plasma cells. 18 F-FDG PET serves as a valuable instrument for initial staging and treatment monitoring in multiple myeloma management. Thus, 18 F-FDG PET can be legitimately applied for TEMPI assessment. Here, we present the first 18 F-FDG PET images for the initial evaluation and treatment monitoring of TEMPI in a 51-year-old woman, who exhibited polycythemia (EPO:5,448 mIU/ml) without JAK2 mutation, telangiectasias, monoclonal IgG lambda gammopathy (13.9) g/L and 7% dysmorphic plasma cells (CD38 + CD138+), occasionally clustered, in favor of tumoral plasmacytomas. The first PET scan exhibited hypermetabolic diffuse bone marrow, potentially related to polycythemia, accompanied by non-lytic bone hypermetabolic lesions in the femoral and humeral diaphysis, and ametabolic peri-renal fluid collections, brown fat, and pleural talcoma. Post-treatment 18 F-FDG PET (Daratumumab Bortezomib Thalidomide Dexamethasone) revealed a completely reduced signal of bone lesions, suggesting a complete response, which was substantiated both clinically and biologically, with the concurrent disappearance of telangiectasia and the monoclonal component, and the normalization of the EPO level. In future, additional data will be required to confirm the added value of 18 F-FDG PET with TEMPI. Nevertheless, 18 F-FDG PET can be a preferred tool for the extension workup and therapeutic evaluation of TEMPI syndrome.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134906255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging theragnostic radionuclide applications for hepatocellular carcinoma 新型放射性核素在肝细胞癌诊断中的应用
Pub Date : 2023-10-25 DOI: 10.3389/fnume.2023.1210982
N. E. Nyakale, C. Aldous, A. A. Gutta, X. Khuzwayo, L. Harry, M. M. Sathekge
Hepatocellular carcinoma (HCC) is a major global health problem. Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine. Theragnostic in HCC involves the use of imaging techniques to diagnose the cancer and assess its characteristics, such as size, location, and extent of spread. Theragnostic involves the use of molecular and genetic tests to identify specific biomarkers that can help guide treatment decisions and post treatment assess the dosimetry and localization of the treatment, thus assisting to guide future treatment. This can be done through either positron emission tomography (PET) scanning or single photon emission tomography (SPECT) using radiolabelled tracers that target specific molecules expressed by HCC cells or radioembolization. This technique can help identify the location and extent of the cancer, as well as provide information on the tumour's metabolic activity and blood supply. In summary, theragnostic is an emerging field that holds promise for improving the diagnosis and treatment of HCC. By combining diagnostic and therapeutic modalities into a single system, theragnostic can help guide personalized treatment decisions and improve patient outcomes.
肝细胞癌(HCC)是一个主要的全球健康问题。治疗是一个术语,指的是将诊断和治疗方式整合到一个个性化医疗的单一系统中。HCC的诊断包括使用影像学技术来诊断癌症并评估其特征,如大小、位置和扩散程度。治疗诊断包括使用分子和基因测试来识别特定的生物标志物,这些生物标志物可以帮助指导治疗决策,并在治疗后评估治疗的剂量和定位,从而帮助指导未来的治疗。这可以通过正电子发射断层扫描(PET)或单光子发射断层扫描(SPECT)来完成,使用放射性标记的示踪剂来靶向HCC细胞表达的特定分子或放射性栓塞。这项技术可以帮助确定癌症的位置和范围,并提供有关肿瘤代谢活动和血液供应的信息。总之,诊断是一个新兴的领域,有望改善HCC的诊断和治疗。通过将诊断和治疗方式结合到一个系统中,诊断可以帮助指导个性化的治疗决策并改善患者的预后。
{"title":"Emerging theragnostic radionuclide applications for hepatocellular carcinoma","authors":"N. E. Nyakale, C. Aldous, A. A. Gutta, X. Khuzwayo, L. Harry, M. M. Sathekge","doi":"10.3389/fnume.2023.1210982","DOIUrl":"https://doi.org/10.3389/fnume.2023.1210982","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a major global health problem. Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine. Theragnostic in HCC involves the use of imaging techniques to diagnose the cancer and assess its characteristics, such as size, location, and extent of spread. Theragnostic involves the use of molecular and genetic tests to identify specific biomarkers that can help guide treatment decisions and post treatment assess the dosimetry and localization of the treatment, thus assisting to guide future treatment. This can be done through either positron emission tomography (PET) scanning or single photon emission tomography (SPECT) using radiolabelled tracers that target specific molecules expressed by HCC cells or radioembolization. This technique can help identify the location and extent of the cancer, as well as provide information on the tumour's metabolic activity and blood supply. In summary, theragnostic is an emerging field that holds promise for improving the diagnosis and treatment of HCC. By combining diagnostic and therapeutic modalities into a single system, theragnostic can help guide personalized treatment decisions and improve patient outcomes.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135218429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiopharmaceutical administration practices—Are they best practice? 放射性药物管理规范-它们是最佳规范吗?
Pub Date : 2023-10-13 DOI: 10.3389/fnume.2023.1244660
Stephen Harris, James R. Crowley, Nancy Warden
Background The nuclear medicine community has stated that they are using best practices to gain venous access and administer radiopharmaceuticals, and therefore do not contribute to extravasations. We tested this hypothesis qualitatively and quantitatively by evaluating four different perspectives of current radiopharmaceutical administration practices: (1) clinical observations of nuclear medicine technologists on the job, (2) quality improvement (QI) projects, (3) a high-level survey of current practices in 10 acute care hospitals, (4) intravenous (IV) access site data for 29,343 procedures. These four areas were compared to the gold standard of pharmaceutical administration techniques. Results From clinical observations of radiopharmaceutical administrations in adult populations, technologists extensively used 24-gauge peripheral intravenous catheters (PIVCs) and butterfly needles. They also performed direct puncture (straight stick). Technologists predominantly chose veins in areas of flexion (hand, wrist, and antecubital fossa), rather than forearm vessels for IV access placement; in many circumstances, antecubital fossa vessels are chosen first, often without prior assessment for other suitable vessels. For selecting the injection vein, technologists sometimes used infrared vein finders but primarily performed blind sticks. Review of QI projects suggested that smaller gauge needles were contributing factors to extravasations. Additionally, the review of surveys from 10 hospitals revealed an absence of formalized protocols, training, knowledge, and skills necessary to ensure the safety/patency of IV devices prior to the administration of radiopharmaceuticals. Finally, findings from a review of IV access data for 29,343 procedures supported the observations described above. Conclusions We expect that nuclear medicine technologists have the best intentions when providing patient care, but many do not follow venous access best practices; they lack formal protocols, have not received the latest comprehensive training, and do not use the best placement tools and monitoring equipment. Thus, the presumption that most nuclear medicine technologists use best practices may not be accurate. In order to improve radiopharmaceutical administration and patient care, the nuclear medicine community should update technical standards to address the most recent peripheral IV access and administration best practices, provide technologists with vascular visualization tools and the proper training, develop and require annual vascular access competency, and provide active monitoring with center and patient-specific data to create ongoing feedback.
核医学界已经声明,他们正在使用最佳做法来获得静脉通路和管理放射性药物,因此不会导致外渗。我们通过评估当前放射性药物管理实践的四个不同视角,定性和定量地检验了这一假设:(1)在职核医学技术人员的临床观察,(2)质量改进(QI)项目,(3)对10家急症护理医院当前实践的高层调查,(4)29,343例手术的静脉注射(IV)访问现场数据。将这四个方面与药事管理技术的金标准进行了比较。结果从成人放射性药物给药的临床观察来看,技术人员广泛使用24号外周静脉导管(pivc)和蝴蝶针。他们还进行了直接穿刺(直棒)。技术人员主要选择屈曲部位的静脉(手、手腕和肘前窝),而不是前臂血管进行静脉注射;在许多情况下,首先选择肘前窝血管,通常没有事先评估其他合适的血管。为了选择注射静脉,技术人员有时使用红外静脉探测仪,但主要是盲棒。对QI项目的回顾表明,较小的针头是造成外渗的因素。此外,对10家医院调查的审查显示,在使用放射性药物之前,缺乏确保静脉注射装置安全/通畅所需的正式规程、培训、知识和技能。最后,对29343例静脉注射数据的回顾结果支持了上述观察结果。结论:我们期望核医学技术人员在提供患者护理时有最好的意图,但许多人没有遵循静脉通路的最佳做法;他们缺乏正式的协议,没有接受过最新的全面培训,也没有使用最好的安置工具和监测设备。因此,大多数核医学技术人员使用最佳实践的假设可能不准确。为了改善放射性药物管理和患者护理,核医学界应该更新技术标准,以解决最新的外周静脉注射和管理最佳实践,为技术人员提供血管可视化工具和适当的培训,发展和要求每年血管进入能力,并提供中心和患者特定数据的主动监测,以创建持续的反馈。
{"title":"Radiopharmaceutical administration practices—Are they best practice?","authors":"Stephen Harris, James R. Crowley, Nancy Warden","doi":"10.3389/fnume.2023.1244660","DOIUrl":"https://doi.org/10.3389/fnume.2023.1244660","url":null,"abstract":"Background The nuclear medicine community has stated that they are using best practices to gain venous access and administer radiopharmaceuticals, and therefore do not contribute to extravasations. We tested this hypothesis qualitatively and quantitatively by evaluating four different perspectives of current radiopharmaceutical administration practices: (1) clinical observations of nuclear medicine technologists on the job, (2) quality improvement (QI) projects, (3) a high-level survey of current practices in 10 acute care hospitals, (4) intravenous (IV) access site data for 29,343 procedures. These four areas were compared to the gold standard of pharmaceutical administration techniques. Results From clinical observations of radiopharmaceutical administrations in adult populations, technologists extensively used 24-gauge peripheral intravenous catheters (PIVCs) and butterfly needles. They also performed direct puncture (straight stick). Technologists predominantly chose veins in areas of flexion (hand, wrist, and antecubital fossa), rather than forearm vessels for IV access placement; in many circumstances, antecubital fossa vessels are chosen first, often without prior assessment for other suitable vessels. For selecting the injection vein, technologists sometimes used infrared vein finders but primarily performed blind sticks. Review of QI projects suggested that smaller gauge needles were contributing factors to extravasations. Additionally, the review of surveys from 10 hospitals revealed an absence of formalized protocols, training, knowledge, and skills necessary to ensure the safety/patency of IV devices prior to the administration of radiopharmaceuticals. Finally, findings from a review of IV access data for 29,343 procedures supported the observations described above. Conclusions We expect that nuclear medicine technologists have the best intentions when providing patient care, but many do not follow venous access best practices; they lack formal protocols, have not received the latest comprehensive training, and do not use the best placement tools and monitoring equipment. Thus, the presumption that most nuclear medicine technologists use best practices may not be accurate. In order to improve radiopharmaceutical administration and patient care, the nuclear medicine community should update technical standards to address the most recent peripheral IV access and administration best practices, provide technologists with vascular visualization tools and the proper training, develop and require annual vascular access competency, and provide active monitoring with center and patient-specific data to create ongoing feedback.","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135854885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in nuclear medicine (Lausanne, Switzerland)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1